Related Experiment Video
Updated: Aug 22, 2026

Live Imaging and Characterization of Microglia Dynamics and Interactions with Synapses in Diseased Murine Retina
Published on: January 16, 2026
Minireview: PRKAR1A: normal and abnormal functions
Ioannis Bossis1, Constantine A Stratakis
1Section on Endocrinology and Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1862, USA.
Insights
The PRKAR1A gene, encoding the RIalpha subunit of cAMP-dependent protein kinase (PKA), is linked to Carney complex due to inactivating mutations. While implicated in tumorigenesis, its role as a classic tumor suppressor gene is questioned.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- The RIalpha subunit (PRKAR1A) is central to cAMP-dependent protein kinase (PKA) holoenzyme activity.
- Carney complex (CNC) is a neoplasia syndrome caused by PRKAR1A-inactivating mutations.
- RIalpha and PRKAR1A mRNA are upregulated in various neoplasms, suggesting roles in tumorigenesis.
Purpose of the Study:
- To explore the multifaceted role of PRKAR1A in tumorigenesis.
- To investigate whether PRKAR1A functions as a classic tumor suppressor gene.
Main Methods:
- Review of existing literature on PRKAR1A, PKA, and Carney complex.
- Analysis of gene expression data and mutation studies related to PRKAR1A in neoplasms.
Main Results:
- PRKAR1A mutations cause Carney complex, indicating a tumor suppressor role in specific contexts.
- Upregulation of RIalpha and PRKAR1A mRNA in neoplasms suggests broader involvement in cancer.
- PKA activity alterations have diverse effects based on cellular context.
Conclusions:
- PRKAR1A's role in tumorigenesis is complex, potentially involving both tumor suppression and oncogenic functions.
- PRKAR1A likely does not fit the definition of a classic tumor suppressor gene.
- Further research is needed to elucidate the non-canonical functions of RIalpha and PRKAR1A.
Abstract:
The type 1alpha regulatory subunit (RIalpha) of cAMP-dependent protein kinase (PKA) (coded by the PRKAR1A gene) is the main component of type I PKA, which regulates most of the serine-threonine kinase activity catalyzed by the PKA holoenzyme in response to cAMP. Carney complex (CNC), or the complex of spotty skin pigmentation, myxomas, and endocrine overactivity, is a multiple endocrine (and not only) neoplasia syndrome that is due to PRKAR1A-inactivating mutations. The R1alpha protein and PRKAR1A mRNA have been found to be up-regulated in a series of cell lines and human and rodent neoplasms, suggesting this molecule's involvement in tumorigenesis and its potential role in cell cycle regulation, growth, and/or proliferation. Alterations in PKA activity elicit a variety of effects depending on the tissue, developmental stage, degree of differentiation, and cAMP levels. In addition, RIalpha may have functions independent of PKA. The presence of inactivating germline mutations and the loss of its wild-type allele in some CNC lesions indicate that PRKAR1A might function as a tumor suppressor gene in these tissues, but could PRKAR1A be a classic tumor suppressor gene? Probably not, and this review explains why.
Related Concept Videos
Abnormal Proliferation
Microtubules in Signaling
Neural Regulation